BMO Capital Initiates Coverage On ACADIA Pharmaceuticals with Outperform Rating, Announces Price Target of $31
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has initiated coverage on ACADIA Pharmaceuticals with an Outperform rating and set a price target of $31.
June 27, 2024 | 9:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has initiated coverage on ACADIA Pharmaceuticals with an Outperform rating and set a price target of $31.
The initiation of coverage with an Outperform rating and a specific price target of $31 by BMO Capital is likely to positively influence investor sentiment and drive short-term price appreciation for ACADIA Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100